Our Work in HIV

Since the first HIV products became available nearly two decades ago, MSD has worked to expand access to our medicines, build healthcare infrastructure, and address health and development challenges around the world.

WORLDWIDE

Approximately 36.9 MILLION
people were living with HIV at
the end of 2014

Approximately 2 MILLION
people became newly infected
with HIV in 2014

%

It is estimated that currently only 51% of people with HIV know
their status

OUR 30-YEAR COMMITMENT TO HIV/AIDS

In the mid-1980s, MSD began its clinical HIV research in response to what the company perceived as a potential epidemic – our scientists were among the first to discover and develop medicines for the treatment of HIV. Today, a future where HIV/AIDS can be a manageable illness is closer, in part, because of MSD’s response to the crisis.

LEARN MORE

IT TAKES A MULTIFACETED APPROACH TO IMPROVE ACCESS

We continue to explore ways to enhance access to our HIV medicines, particularly in the developing world, and through partnerships that seek to strengthen health systems to better deliver prevention and treatment services. Clearly, the need is too great for any one stakeholder to address, requiring coordinated efforts among many. We are committed to working with governments, donors, innovative and generic manufacturers, multilateral organizations and civil society to address the full range of factors affecting access.

LEARN MORE